Sheri McCoy became a director of Novocure in May 2018. From 2012 to 2018, Ms. McCoy was the Chief Executive Officer of Avon Products Inc., a direct selling company in beauty, household and personal care categories. Prior to joining Avon, Ms. McCoy had various roles at Johnson & Johnson, most recently serving as vice chairman of the executive committee and member of the office of the chairman, where she was responsible for the pharmaceutical and consumer business divisions of the company. She brings substantial general business leadership and innovation knowledge and experience as a senior leader of two global Fortune 500 companies. Ms. McCoy holds four U.S. patents and has been on Fortune Magazine’s “50 Most Powerful Women in Business” list beginning in 2008. In August 2012, she was recognized as the 39th most powerful woman in the world by Forbes. Ms. McCoy is also a director of AstraZeneca, PLC and Stryker Corporation. She holds a bachelor’s degree in textile chemistry from the University of Massachusetts, Dartmouth, a master’s degree in chemical engineering from Princeton University, and an MBA from Rutgers University.
novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma and mesothelioma. Novocure has ongoing or completed clinical trials investigating our therapy in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.